Adjuvant Chemotherapy Key to Improving OS in Rectal Cancer
A retrospective study shows 30 patients need to be treated with adjuvant therapy to prevent 1 death at 3 years.
Potential Role for Vaccines, Checkpoint Inhibitors in Chemoprevention of Lynch Syndrome
Researchers from MD Anderson say their study results "open the field of immunoprevention in LS to checkpoint inhibitors as an immune interception strategy."
Patient and Tumor Features Predicted RCC Outcomes Post Nephrectomy
Routinely available patient and tumor features accurately predicted the risk progression and death from RCC post nephrectomy, a Mayo Clinic team found.
Discovery of Genes Linked to Myeloma Onset May Drive Personalized Tx
A UK team found multiple targets of non-coding mutations, highlighting the importance of broadening the search for cancer drivers into the regulatory genome.
Maintenance Bortezomib: No Improved Depth of Response in “Plateaued” MM
Investigators concluded further investigations are warranted in elderly patients with either stable or responsive disease after bortezomib induction therapy.
New CABOSUN Data Show Better PFS With Cabozantinib in mRCC
The significantly better PFS compared with sunitinib supports cabozantinib as initial therapy for patients with advanced RCC of intermediate or poor risk.
Interim MRD May Help Direct Individual Treatment for CLL
Achieving undetectable MRD after chemoimmunotherapy predicted longer progression-free and overall survival in CLL patients.
Venetoclax/Rituximab Found Superior to Chemotherapy in CLL
The combination of rituximab and the BCL2 inhibitor venetoclax significantly lengthened PFS among CLL patients in the phase III MURANO trial.
Duvelisib Granted Priority Review for R/R CLL/SLL and FL
In the DUO and DYNAMO trials, duvelisib improved clinical responses in patients with R/R CLL/SLL and FL, respectively.
Antibiotics Reduced Efficacy of Checkpoint Inhibitors in RCC, NSCLC
Antibiotics administered within 30 days of starting immunotherapy reduced both PFS and OS for patients with advanced RCC and NSCLC.
Modified XELIRI Noninferior to FOLFIRI for Metastatic CRC
mXELIRI could be practice-changing by providing an alternative to irinotecan-based regimens for some patients, but may not work in non-Asian populations.
Less Risk of Distal Colon Cancer With Lower Red Meat Intake?
A large prospective analysis of data from the UK Women’s Cohort Study found an association between red meat consumption and distal colon disease risk.
Excess Mortality Risk Shows Myeloma Is Still ‘Incurable’
Three year OS was significantly worse compared with the general population, with a persistent risk for relapse.
First-Line Avelumab/Axitinib Encouraging in Advanced RCC
First-line combination therapy with the PD-L1 inhibitor avelumab and the VEGFR TKI axitinib yielded antitumor activity in previously untreated RCC.
High BMI in Early Adulthood Increased Myeloma Risk
A large prospective analysis of three large cohorts found a positive link between risk for myeloma and cumulative average young adult and adult BMI.
TNT Is Viable for Locally Advanced Rectal Cancer
CR was 36% in the total neoadjuvant therapy cohort vs 21% in the cohort that received chemoradiotherapy with adjuvant chemotherapy.
TIVO-1 Crossover: Tivozanib Active for Advanced RCC
Compared with sorafenib, tivozanib significantly improved PFS and OS, and yielded significantly higher ORRs, a crossover analysis of TIVO-1 found.
Pan-PI3K Inhibitor Voxtalisib Active in FL but Less So in CLL, DLBCL
In a phase II study, voxtalisib, which targets all four class I PI3Ks, had efficacy in FL but limited clinical effect in MCL, DLBCL, and CLL/SLL.
Statin Use Linked With Decreased Risk for DLBCL
In this large population-based, case-control study, having ever used a statin was linked to lower risk of total NHL and certain NHL subtypes, including DLBCL.
BET Inhibitors Active in DLBCL and Other Lymphomas, Two Early Trials Show
BET inhibitors CPI-1205 and CPI-0610 have shown promise in two phase I trials in DLBCL and other lymphomas, investigators at TAT 2018 reported.
Incidence of Merkel Cell Carcinoma Rising Sharply
The incidence of Merkel cell carcinoma, an aggressive neuroendocrine skin cancer, has grown rapidly since the disease was first described in 1972.
International CLL Group Updates Trials Guidelines
The International Workshop on Chronic Lymphocytic Leukemia has updated its 2008 consensus guidelines for design and conduct of CLL clinical trials.
NCCN: New Guidelines on Care of HIV Concurrent With Cancer
The NCCN has released new clinical practice guidelines for the management of cancer in people living with HIV.
Anti–Oral Mucositis Drug Granted Breakthrough Status
The FDA has granted Breakthrough Therapy and Fast Track designation to GC4419, for reduction of severe oral mucositis caused by radiation therapy.
Obesity Surgery Did Not Increase Risk for Subsequent Colorectal Cancer
In this UK observational study, being obese was linked with an increased risk for colorectal cancer but undergoing prior obesity surgery was not.
Ixazomib Triplet Combo Effective in R/R Myeloma
The oral therapy combination of ixazomib, pomalidomide, and dexamethasone was effective and well-tolerated in patients with myeloma that had relapsed or was refractory to lenalidomide.
Certain RCC Subgroups May Benefit From Partial vs Radical Nephrectomy
In a large Chinese study, in certain RCC subgroups cancer-specific survival outcomes were better with partial rather than radical nephrectomy.
Antibiotics Could Reduce Diarrhea, Improve Outcomes in Metastatic RCC
Patients who received Bacteroides-targeting antibiotics had a median PFS of 18 months compared with 8 months in patients with no antibiotic use.
PROs Show High Symptom Burden Among Newly Diagnosed Patients With Cancer
Earlier collection of patient-reported outcomes could potentially improve comprehensive cancer care.
Inpatient Chemotherapy Is Appropriate for DLBCL
DLBCL patients who received in-hospital chemotherapy had a lower risk of death during hospitalization.